Choosing between Sermorelin, Ipamorelin, and Tesamorelin

Choosing between Sermorelin, Ipamorelin, and Tesamorelin is one of the most common decisions for someone starting GH-axis peptides. They're not interchangeable. Two of them are GHRH analogs that mimic the natural GHRH signal; one is a ghrelin mimetic that hits a different receptor. They overlap in goal — more endogenous GH release — but differ in mechanism, ceiling, side-effect profile, cost, and legal status.

This is a long, decision-oriented comparison. Mechanisms, dosing realities, cost ranges, where each fits, and a numbered framework matching common goals to the most-defensible starting point.

What each one is

Sermorelin is a 29-amino-acid GHRH analog — basically the first 29 amino acids of natural GHRH, the peptide your hypothalamus releases to stimulate pituitary GH secretion. Closest to natural physiology of the three. Short half-life, gentle effect, long history of off-label use. Has been compounded by some pharmacies for off-label use; status has tightened.

Ipamorelin is a 5-amino-acid synthetic ghrelin mimetic. It binds the GHSR (ghrelin receptor) on the pituitary to stimulate GH release. Different receptor than Sermorelin, complementary pathway. Cleanest side-effect profile of the older GHRPs (compared to GHRP-2 and GHRP-6). Often paired with CJC-1295 in the canonical "Ipa+CJC" stack.

Tesamorelin is a stabilized GHRH analog — closer to Sermorelin's mechanism but engineered for a longer half-life and more pronounced effect. FDA-approved for HIV-associated lipodystrophy. It's the only one of the three with an FDA-approved indication. Off-label use for visceral fat in non-HIV populations exists but isn't the approved use.

Mechanism comparison

The key mechanistic point: Sermorelin and Tesamorelin act via the GHRH receptor; Ipamorelin acts via the ghrelin receptor. That's why pairing a GHRH analog with a ghrelin mimetic — the canonical CJC-1295 + Ipamorelin stack — produces synergistic GH pulses. Two GHRH analogs together don't compound the way a GHRH + GHRP combination does.

Side-by-side comparison

These ranges are typical, not universal. Vendor pricing varies; the relative ordering is what matters.

Effect ceiling comparison

What each can realistically do:

If you're after the "biggest effect of any secretagogue protocol" — Tesamorelin is closest. If you're after "gentle baseline lift" — Sermorelin. If you're after "best stacking partner for a synergistic protocol" — Ipamorelin.

Cost reality

Sermorelin is the cheapest of the three. Tesamorelin is by far the most expensive — sometimes 3-4x Sermorelin per cycle — because of its FDA-approved status and the manufacturing involved. Ipamorelin alone is close to Sermorelin in cost; the practical use of Ipamorelin is in a stack with CJC-1295, which raises the cost.

For a 12-week cycle, US ranges:

Insurance coverage of Tesamorelin is real for HIV-LD — that's the FDA-approved use. Off-label, expect to pay out of pocket.

Side effect comparison

Ipamorelin's cleanness is part of why it became the default GHRP. The older alternatives (GHRP-2, GHRP-6) tend to spike cortisol, prolactin, and hunger more. Sermorelin's mildness is consistent with its physiologic mechanism. Tesamorelin's stronger effect comes with stronger downsides.

Stacking considerations

Sermorelin and Tesamorelin are both GHRH analogs. They don't usually stack with each other — same receptor, redundant signal. You'd pick one or the other.

Ipamorelin is the natural stack partner for either. The most-reported stack is Ipamorelin + CJC-1295 (no DAC) — Ipa hits the ghrelin receptor, CJC hits the GHRH receptor, the two pathways converge synergistically. Some protocols substitute Sermorelin or Tesamorelin for CJC, which is mechanistically sound but uses a more expensive GHRH partner.

A few stacking patterns:

• Ipamorelin + CJC-1295 (no DAC): the canonical stack
• Ipamorelin + Sermorelin: mechanistically similar to above, slightly different kinetics
• Tesamorelin alone: for visceral fat focus; usually run solo
• Sermorelin alone: for first-time users wanting gentle introduction

Legal and regulatory status

This is where the three diverge most.

• Tesamorelin is FDA-approved for HIV-LD. Prescription required; off-label prescription possible with a willing physician.
• Sermorelin has historically been compounded by some 503A pharmacies for off-label use. Status has tightened. Prescription required for compounded forms.
• Ipamorelin is a research chemical. Not FDA-approved for any indication. Possession is in the same legal zone as most other research peptides.

For someone deciding which to start with, the legal calculus matters. Tesamorelin via prescription is on much firmer ground than Ipamorelin from a research-chem vendor — but the cost and access barriers are also higher.

Decision framework

1. First-ever GH-axis peptide, want gentlest entry. Sermorelin alone, 12-week cycle, single nightly SubQ. Cheapest, mildest, easiest to evaluate.

2. First cycle didn't move the needle, want stronger effect. Switch to Ipamorelin + CJC-1295 (no DAC). Different mechanism, synergistic pulses, still affordable.

3. Visceral fat reduction the dominant goal, especially HIV-LD context. Tesamorelin. FDA-approved, strongest evidence for the visceral-fat use case, may be insurance-covered.

4. Want maximum legal defensibility, willing to pay for it. Tesamorelin via prescription. Sermorelin via compounded prescription if available.

5. Budget the limiting factor. Sermorelin alone, or Ipamorelin alone if you specifically want the ghrelin pathway.

6. Sleep quality the dominant goal. Ipamorelin + CJC-1295 (no DAC) is the most-reported for this. Sermorelin a reasonable second.

7. Recovery emphasis with body-comp secondary. Ipamorelin + CJC-1295. Sermorelin if budget tight.

8. Diabetic, prediabetic, or strong family history of insulin resistance. Sermorelin or Ipamorelin over Tesamorelin. Glucose monitoring on any of them.

9. Active or recent cancer. None without an oncology-aware conversation. GH-axis stimulation is not a self-decision in that context.

When none of these are the answer

Worth saying directly. These are not the right tool when:

• The pituitary is dysfunctional and can't release GH; you need replacement (synthetic HGH under clinical care), not stimulation
• The goal is dramatic muscle gain; secretagogues don't deliver anabolic-class results
• The goal is reversing aging globally; the marketing oversells what these can do
• The underlying issue is sleep deprivation, undereating, or chronic stress; no peptide outruns those
• Active or recent malignancy is in the picture

A secretagogue is a multiplier on a working pituitary axis. It's not an ignition for a system that isn't running.

Related reading

• GH secretagogues complete guide
• Sermorelin protocol
• Ipamorelin protocol
• Tesamorelin protocol
• Ipamorelin + CJC-1295 stack